We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Apatinib treatment for KIT- and KDR-amplified angiosarcoma: a case report.
- Authors
Yang, Lishu; Liu, Lizhu; Han, Bo; Han, Wei; Zhao, Meng
- Abstract
<bold>Background: </bold>Metastatic or relapsed angiosarcoma has a poor prognosis and the efficacy of conventional chemotherapy is often limited. Apatinib, a novel tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptor-2 (VEGFR2), has been approved for the treatment of advanced gastric cancer.<bold>Case Presentation: </bold>Herein, we report a patient with advanced angiosarcoma, who received apatinib at a daily dose of 250 to 725 mg, resulting in a partial response for three months, which may be related to Kinase Insert Domain Receptor (KDR) gene amplification.<bold>Conclusion: </bold>Our experience reported here indicated that apatinib may be a useful therapeutic option for treatment of patients with advanced angiosarcoma.
- Subjects
ANGIOSARCOMA; CANCER relapse; METASTASIS; PROTEIN-tyrosine kinase inhibitors; CANCER chemotherapy; ENDOTHELIAL growth factors; ANTINEOPLASTIC agents; PYRIDINE; CELL receptors; GENE amplification; HEAD tumors; NECK tumors; SARCOMA; SCALP; SKIN tumors; TRANSFERASES; THERAPEUTICS
- Publication
BMC Cancer, 2018, Vol 18, Issue 1, p1
- ISSN
1471-2407
- Publication type
journal article
- DOI
10.1186/s12885-018-4523-2